NCT00061945 2022-05-03
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
Clinical Trials
32 trialsNCT00028002 2020-10-26
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
National Cancer Institute (NCI)
Phase 2 Completed
NCT00075400 2019-07-24
Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00068380 2018-07-11
A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00074308 2018-06-20
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00079313 2017-07-02
Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00045734 2017-05-15
Imatinib Mesylate in Treating Patients With Recurrent Meningioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00039585 2015-04-30
Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor
National Cancer Institute (NCI)
Phase 2 Completed
NCT00030667 2015-04-15
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
National Cancer Institute (NCI)
Phase 2 Completed
NCT00470470 2014-12-23
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01281865 2014-10-08
Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00087152 2014-06-09
S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00022737 2014-02-27
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Completed
NCT00039416 2014-02-25
Imatinib Mesylate in Treating Patients With Myelofibrosis
National Cancer Institute (NCI)
Phase 2 Completed
NCT00049569 2013-10-08
Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase NA Completed
NCT00052949 2013-10-08
Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00041197 2013-07-16
Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00015860 2013-06-24
STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00031915 2013-06-19
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00049192 2013-06-04
Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00618501 2013-03-26
Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00068783 2013-02-28
S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00084630 2013-02-28
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025246 2013-02-20
Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00041041 2013-02-20
Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00015834 2013-01-24
STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00041340 2013-01-23
Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00045188 2013-01-23
Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00054431 2013-01-23
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00030394 2013-01-17
Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00026169 2013-01-10
Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
National Cancer Institute (NCI)
Phase 1 Completed
NCT00045604 2008-07-24
Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Completed